{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:23:34Z","timestamp":1789226614627,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"DOI":"10.7759\/cureus.61489","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T13:37:00Z","timestamp":1717249020000},"source":"Crossref","is-referenced-by-count":2,"title":["Immune Checkpoint Inhibitor-Induced Guillain Barre Syndrome: A Single-Institution Case Report and Narrative Review"],"prefix":"10.7759","author":[{"given":"Precious O","family":"Idogun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Hafez-Khayyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ezekwudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2019.11.034","article-title":"Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist","volume":"124","author":"Lewis AL","year":"2020","unstructured":"Lewis AL, Chaft J, Girotra M, Fischer GW. Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist. Br J Anaesth. 2020, 124:251-60. 10.1016\/j.bja.2019.11.034","journal-title":"Br J Anaesth"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2165\/11594010-000000000-00000","article-title":"Ipilimumab: first global approval","volume":"71","author":"Cameron F","year":"2011","unstructured":"Cameron F, Whiteside G, Perry C. Ipilimumab: first global approval. Drugs. 2011, 71:1093-104. 10.2165\/11594010-000000000-00000","journal-title":"Drugs"},{"key":"ref3","article-title":"Nivolumab","author":"Rendon A","year":"2022","unstructured":"Rendon A, Rayi A. Nivolumab. StatPearls [Internet]. Stat Pearls Publishing, Treasure Island, FL; 2022."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/PO.16.00030","article-title":"Programmed cell death 1 (PD-1) ligand (PD-L1) expression in solid tumors as a predictive biomarker of benefit from PD-1\/PD-L1 axis inhibitors: a systematic review and meta-analysis","volume":"1","author":"Khunger M","year":"2017","unstructured":"Khunger M, Hernandez AV, Pasupuleti V, et al.. Programmed cell death 1 (PD-1) ligand (PD-L1) expression in solid tumors as a predictive biomarker of benefit from PD-1\/PD-L1 axis inhibitors: a systematic review and meta-analysis. JCO Precis Oncol. 2017, 1:1-15. 10.1200\/PO.16.00030","journal-title":"JCO Precis Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2020.2042","article-title":"Guillain-Barre syndrome induced by pembrolizumab and sunitinib: a case report","volume":"13","author":"Han C","year":"2020","unstructured":"Han C, Ma JA, Zhang Y, Jiang Y, Hu C, Wu Y. Guillain-Barre syndrome induced by pembrolizumab and sunitinib: a case report. Mol Clin Oncol. 2020, 13:38-42. 10.3892\/mco.2020.2042","journal-title":"Mol Clin Oncol"},{"key":"ref6","article-title":"Guillain-Barre syndrome","author":"Nguyen TP","year":"2023","unstructured":"Nguyen TP, Taylor RS. Guillain-Barre syndrome. StatPearls [Internet].  StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"388","author":"Willison HJ","year":"2016","unstructured":"Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barr\u00e9 syndrome. Lancet. 2016, 388:717-27. 10.1016\/S0140-6736(16)00339-1","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.608130","article-title":"Intensive care and treatment of severe Guillain-Barr\u00e9 syndrome","volume":"12","author":"Shang P","year":"2021","unstructured":"Shang P, Feng J, Wu W, Zhang HL. Intensive care and treatment of severe Guillain-Barr\u00e9 syndrome. Front Pharmacol. 2021, 12:608130. 10.3389\/fphar.2021.608130","journal-title":"Front Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde PM","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, et al.. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022, 386:1973-85. 10.1056\/NEJMoa2202170","journal-title":"N Engl J Med"},{"key":"ref10","unstructured":"Overview of Immune Checkpoint Inhibitors in NSCLC. Targeted Oncology. (2023). Accessed. August 18: https:\/\/www.targetedonc.com\/view\/overview-of-immune-checkpoint-inhibitors-in-nsclc."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/11795549211056261","article-title":"Neurological adverse events induced by immune checkpoint inhibitors in non-small cell lung cancer: current perspectives and new development","volume":"15","author":"Cheng K","year":"2021","unstructured":"Cheng K, Wang Y, Zhou Y, Xia R, Tang L, Liu J. Neurological adverse events induced by immune checkpoint inhibitors in non-small cell lung cancer: current perspectives and new development. Clin Med Insights Oncol. 2021, 15:11795549211056261. 10.1177\/11795549211056261","journal-title":"Clin Med Insights Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy LB","year":"2020","unstructured":"Kennedy LB, Salama AK. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020, 70:86-104. 10.3322\/caac.21596","journal-title":"CA Cancer J Clin"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov I","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al.. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017, 5:95.","journal-title":"J Immunother Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis","volume":"22","author":"Larkin J","year":"2017","unstructured":"Larkin J, Chmielowski B, Lao CD, et al.. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017, 22:709-18. 10.1634\/theoncologist.2016-0487","journal-title":"Oncologist"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.7722","article-title":"Association of immune checkpoint inhibitors with neurologic adverse events: a systematic review and meta-analysis","volume":"5","author":"Farooq MZ","year":"2022","unstructured":"Farooq MZ, Aqeel SB, Lingamaneni P, et al.. Association of immune checkpoint inhibitors with neurologic adverse events: a systematic review and meta-analysis. JAMA Netw Open. 2022, 5:e227722. 10.1001\/jamanetworkopen.2022.7722","journal-title":"JAMA Netw Open"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.005","article-title":"Neurologic complications of immune checkpoint inhibitors in thoracic malignancies","volume":"16","author":"Sechi E","year":"2021","unstructured":"Sechi E, Zekeridou A. Neurologic complications of immune checkpoint inhibitors in thoracic malignancies. J Thorac Oncol. 2021, 16:381-94. 10.1016\/j.jtho.2020.11.005","journal-title":"J Thorac Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25708","article-title":"Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum","volume":"87","author":"Dubey D","year":"2020","unstructured":"Dubey D, David WS, Reynolds KL, et al.. Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol. 2020, 87:659-69. 10.1002\/ana.25708","journal-title":"Ann Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9800488","article-title":"Guillain-Barr\u00e9 syndrome-like polyneuropathy associated with immune checkpoint inhibitors: a systematic review of 33 cases","volume":"2021","author":"Li Y","year":"2021","unstructured":"Li Y, Zhang X, Zhao C. Guillain-Barr\u00e9 syndrome-like polyneuropathy associated with immune checkpoint inhibitors: a systematic review of 33 cases. Biomed Res Int. 2021, 2021:9800488. 10.1155\/2021\/9800488","journal-title":"Biomed Res Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e13725","article-title":"Evaluation and management of acute high-grade immunotherapy-related neurotoxicity","volume":"9","author":"Sandoval M","year":"2023","unstructured":"Sandoval M, Wechsler AH, Alhajji Z, et al.. Evaluation and management of acute high-grade immunotherapy-related neurotoxicity. Heliyon. 2023, 9:e13725. 10.1016\/j.heliyon.2023.e13725","journal-title":"Heliyon"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10404-0","article-title":"Guillain-Barr\u00e9 syndrome in patients treated with immune checkpoint inhibitors","volume":"268","author":"Fan Q","year":"2021","unstructured":"Fan Q, Hu Y, Wang X, Zhao B. Guillain-Barr\u00e9 syndrome in patients treated with immune checkpoint inhibitors. J Neurol. 2021, 268:2169-74. 10.1007\/s00415-021-10404-0","journal-title":"J Neurol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini A","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL, Valente M, Mu\u00f1iz-Castrillo S, Honnorat J, Vogrig A. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology. 2021, 96:754-66. 10.1212\/WNL.0000000000011795","journal-title":"Neurology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.31579\/2578-8868\/177","article-title":"Neurological diseases associated to immune checkpoint inhibitors","volume":"8","author":"Souza F","year":"2021","unstructured":"Souza F. Neurological diseases associated to immune checkpoint inhibitors. Neurosci Neurol Surg. 2021, 8:01-08. 10.31579\/2578-8868\/177","journal-title":"Neurosci Neurol Surg"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard SE","year":"2019","unstructured":"Leonhard SE, Mandarakas MR, Gondim FA, et al.. Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps. Nat Rev Neurol. 2019, 15:671-83. 10.1038\/s41582-019-0250-9","journal-title":"Nat Rev Neurol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14600","article-title":"Cerebrospinal fluid protein in Guillain-Barr\u00e9 syndrome: need for age-dependent interpretation","volume":"28","author":"Hegen H","year":"2021","unstructured":"Hegen H, Ladst\u00e4tter F, Bsteh G, et al.. Cerebrospinal fluid protein in Guillain-Barr\u00e9 syndrome: need for age-dependent interpretation. Eur J Neurol. 2021, 28:965-73. 10.1111\/ene.14600","journal-title":"Eur J Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2005.07.009","article-title":"Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA","volume":"239","author":"Kuijf ML","year":"2005","unstructured":"Kuijf ML, van Doorn PA, Tio-Gillen AP, et al.. Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J Neurol Sci. 2005, 239:37-44. 10.1016\/j.jns.2005.07.009","journal-title":"J Neurol Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.47.3.813","article-title":"Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barr\u00e9 syndrome","volume":"47","author":"Gorson KC","year":"1996","unstructured":"Gorson KC, Ropper AH, Muriello MA, Blair R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barr\u00e9 syndrome. Neurology. 1996, 47:813-7. 10.1212\/wnl.47.3.813","journal-title":"Neurology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000364","article-title":"Immune checkpoint inhibitor-related Guillain-Barr\u00e9 syndrome: a case series and review of the literature","volume":"44","author":"Janssen JB","year":"2021","unstructured":"Janssen JB, Leow TY, Herbschleb KH, Gijtenbeek JM, Boers-Sonderen MJ, Gerritsen WR, Westdorp H. Immune checkpoint inhibitor-related Guillain-Barr\u00e9 syndrome: a case series and review of the literature. J Immunother. 2021, 44:276-82. 10.1097\/CJI.0000000000000364","journal-title":"J Immunother"},{"key":"ref28","article-title":"Adjunctive steroid therapy for Guillain-Barr\u00e9 syndrome","volume":"2004","author":"Walling AD","unstructured":"Walling AD. Adjunctive steroid therapy for Guillain-Barr\u00e9 syndrome. Am Fam Physician. 2004:1157-61.","journal-title":"Am Fam Physician"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1132692","article-title":"Case report: ICIs-induced Guillain-Barr\u00e9 syndrome recovered from mycophenolate mofetil","volume":"14","author":"Ding M","year":"2023","unstructured":"Ding M, Deng C, Liu X, et al.. Case report: ICIs-induced Guillain-Barr\u00e9 syndrome recovered from mycophenolate mofetil. Front Immunol. 2023, 14:1132692. 10.3389\/fimmu.2023.1132692","journal-title":"Front Immunol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.35.15_suppl.9012","article-title":"Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy","volume":"35","author":"Santini FC","year":"2017","unstructured":"Santini FC, Rizvi H, Wilkins O, et al.. Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy. J Clin Oncol. 2017, 35:9012. 10.1200\/jco.2017.35.15_suppl.9012","journal-title":"J Clin Oncol"},{"key":"ref32","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-021-06480-5","article-title":"Immunotherapy toxicity: identification and management","volume":"192","author":"Gumusay O","year":"2022","unstructured":"Gumusay O, Callan J, Rugo HS. Immunotherapy toxicity: identification and management. Breast Cancer Res Treat. 2022, 192:1-17.","journal-title":"Breast Cancer Res Treat"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.55522\/jmpas.V11S1.1249","article-title":"Physiotherapy management of a 23year old adult with Guillain-Barre syndrome (GBS)","volume":"11","author":"Yadav M","year":"2022","unstructured":"Yadav M, Thombare N, Phansopkar P. Physiotherapy management of a 23year old adult with Guillain-Barre syndrome (GBS). J Med Pharm Allied Sci. 2022, 11:10.55522\/jmpas.V11S1.1249","journal-title":"J Med Pharm Allied Sci"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.11.022","article-title":"Guillain-Barr\u00e9 syndrome related to nivolumab: case report of a patient with urothelial cancer and review of the literature","volume":"17","author":"Kyriazoglou A","year":"2019","unstructured":"Kyriazoglou A, Liontos M, Papadopoulos C, et al.. Guillain-Barr\u00e9 syndrome related to nivolumab: case report of a patient with urothelial cancer and review of the literature. Clin Genitourin Cancer. 2019, 17:e360-4. 10.1016\/j.clgc.2018.11.022","journal-title":"Clin Genitourin Cancer"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyw090","article-title":"Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barr\u00e9 syndrome: a case report","volume":"46","author":"Tanaka R","year":"2016","unstructured":"Tanaka R, Maruyama H, Tomidokoro Y, et al.. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barr\u00e9 syndrome: a case report. Jpn J Clin Oncol. 2016, 46:875-8. 10.1093\/jjco\/hyw090","journal-title":"Jpn J Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2018.04.028","article-title":"Nivolumab-induced acute demyelinating polyradiculoneuropathy mimicking Guillain-Barr\u00e9 syndrome","volume":"390","author":"Nukui T","year":"2018","unstructured":"Nukui T, Nakayama Y, Yamamoto M, et al.. Nivolumab-induced acute demyelinating polyradiculoneuropathy mimicking Guillain-Barr\u00e9 syndrome. J Neurol Sci. 2018, 390:115-6. 10.1016\/j.jns.2018.04.028","journal-title":"J Neurol Sci"},{"key":"ref37","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-230848","article-title":"Isolated adrenocorticotropic hormone (ACTH) deficiency and Guillain-Barr\u00e9 syndrome occurring in a patient treated with nivolumab","volume":"12","author":"Pierrard J","year":"2019","unstructured":"Pierrard J, Petit B, Lejeune S, Seront E. Isolated adrenocorticotropic hormone (ACTH) deficiency and Guillain-Barr\u00e9 syndrome occurring in a patient treated with nivolumab. BMJ Case Rep. 2019, 12:230848.","journal-title":"BMJ Case Rep"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000230","article-title":"Severe relapse of vaccine-induced Guillain-Barr\u00e9 syndrome after treatment with nivolumab","volume":"20","author":"Yuen C","year":"2019","unstructured":"Yuen C, Kamson D, Soliven B, Kramer C, Goldenberg F, Rezania K. Severe relapse of vaccine-induced Guillain-Barr\u00e9 syndrome after treatment with nivolumab. J Clin Neuromuscul Dis. 2019, 20:194-9. 10.1097\/CND.0000000000000230","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-016-2191-7","article-title":"A case of fatal Guillain-Barre syndrome from anti-PD1 monoclonal antibody use","volume":"142","author":"Jacob A","year":"2016","unstructured":"Jacob A, Unnikrishnan DC, Mathew A, Thyagarajan B, Patel S. A case of fatal Guillain-Barre syndrome from anti-PD1 monoclonal antibody use. J Cancer Res Clin Oncol. 2016, 142:1869-70. 10.1007\/s00432-016-2191-7","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000771","article-title":"Nivolumab-associated Guillain-Barre syndrome in a patient with non-small-cell lung cancer","volume":"25","author":"Thapa B","year":"2018","unstructured":"Thapa B, Khalid S, Vakili R, Ui J, Misbah S. Nivolumab-associated Guillain-Barre syndrome in a patient with non-small-cell lung cancer. Am J Ther. 2018, 25:e761-3. 10.1097\/MJT.0000000000000771","journal-title":"Am J Ther"},{"key":"ref41","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2017-316510","article-title":"Acute demyelinating polyneuropathy induced by nivolumab","volume":"89","author":"Fukumoto Y","year":"2018","unstructured":"Fukumoto Y, Kuwahara M, Kawai S, Nakahama K, Kusunoki S. Acute demyelinating polyneuropathy induced by nivolumab. J Neurol Neurosurg Psychiatry. 2018, 89:435-7.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.11.001","article-title":"Nivolumab-induced Guillain-Barr\u00e9 syndrome coupled with remarkable disease response in a case of heavily pretreated lung adenocarcinoma","volume":"21","author":"Mazzaschi G","year":"2020","unstructured":"Mazzaschi G, Bordi P, Fioretzaki R, et al.. Nivolumab-induced Guillain-Barr\u00e9 syndrome coupled with remarkable disease response in a case of heavily pretreated lung adenocarcinoma. Clin Lung Cancer. 2020, 21:e65-73. 10.1016\/j.cllc.2019.11.001","journal-title":"Clin Lung Cancer"},{"key":"ref43","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-2548","article-title":"PD-1 antibody-induced Guillain-Barr\u00e9 syndrome in a patient with metastatic melanoma","volume":"97","author":"Schneiderbauer R","year":"2017","unstructured":"Schneiderbauer R, Schneiderbauer M, Wick W, Enk AH, Haenssle HA, Hassel JC. PD-1 antibody-induced Guillain-Barr\u00e9 syndrome in a patient with metastatic melanoma. Acta Derm Venereol. 2017, 97:395-6.","journal-title":"Acta Derm Venereol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000193","article-title":"Guillain-Barr\u00e9 syndrome triggered by immune checkpoint inhibitors: a case report and literature review","volume":"19","author":"Supakornnumporn S","year":"2017","unstructured":"Supakornnumporn S, Katirji B. Guillain-Barr\u00e9 syndrome triggered by immune checkpoint inhibitors: a case report and literature review. J Clin Neuromuscul Dis. 2017, 19:80-3. 10.1097\/CND.0000000000000193","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000285","article-title":"Nivolumab and ipilimumab-induced acute inflammatory demyelinating polyradiculoneuropathy: a case report","volume":"42","author":"Pomerantz M","year":"2019","unstructured":"Pomerantz M, Lichtenstein DA, Niesvizky-Kogan I, Sohal R, Leibovitch J, Basnet A. Nivolumab and ipilimumab-induced acute inflammatory demyelinating polyradiculoneuropathy: a case report. J Immunother. 2019, 42:348-9. 10.1097\/CJI.0000000000000285","journal-title":"J Immunother"},{"key":"ref46","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-229443","article-title":"A rare case of Miller Fisher variant of Guillain-Barr\u00e9 syndrome (GBS) induced by a checkpoint inhibitor","volume":"12","author":"McNeill CJ","year":"2019","unstructured":"McNeill CJ, Fehmi J, Gladwin J, Price C. A rare case of Miller Fisher variant of Guillain-Barr\u00e9 syndrome (GBS) induced by a checkpoint inhibitor. BMJ Case Rep. 2019, 12:229443.","journal-title":"BMJ Case Rep"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2017.07.014","article-title":"Immune mediated neuropathy following checkpoint immunotherapy","volume":"45","author":"Gu Y","year":"2017","unstructured":"Gu Y, Menzies AM, Long GV, Fernando SL, Herkes G. Immune mediated neuropathy following checkpoint immunotherapy. J Clin Neurosci. 2017, 45:14-7. 10.1016\/j.jocn.2017.07.014","journal-title":"J Clin Neurosci"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1177\/1941874418778957","article-title":"Miller Fisher syndrome associated with immunotherapy for metastatic melanoma","volume":"8","author":"Baird-Gunning JJ","year":"2018","unstructured":"Baird-Gunning JJ, Weerasinghe D, Silsby M, Gawarikar Y, Carlino MS, Smith JL, Vucic S. Miller Fisher syndrome associated with immunotherapy for metastatic melanoma. Neurohospitalist. 2018, 8:191-3. 10.1177\/1941874418778957","journal-title":"Neurohospitalist"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/251582-immune-checkpoint-inhibitor-induced-guillain-barre-syndrome-a-single-institution-case-report-and-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T13:37:08Z","timestamp":1717249028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/251582-immune-checkpoint-inhibitor-induced-guillain-barre-syndrome-a-single-institution-case-report-and-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.61489","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,1]]}}}